R Scott Pearsall

Summary

Publications

  1. pmc A soluble activin type IIA receptor induces bone formation and improves skeletal integrity
    R Scott Pearsall
    Acceleron Pharma, Inc, 149 Sidney Street, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 105:7082-7. 2008
  2. pmc Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth
    Roselyne Castonguay
    Acceleron Pharma, Cambridge, Massachusetts 02139, USA
    J Biol Chem 286:30034-46. 2011
  3. ncbi request reprint Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis
    Rajasekhar N V S Suragani
    Acceleron Pharma, Cambridge, Massachusetts, USA
    Nat Med 20:408-14. 2014
  4. pmc Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia
    Rajasekhar N V S Suragani
    Acceleron Pharma, Cambridge, MA and
    Blood 123:3864-72. 2014
  5. pmc Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb
    Dianne Sako
    Acceleron Pharma, Cambridge, MA 02139, USA
    J Biol Chem 285:21037-48. 2010
  6. pmc Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type
    Samuel M Cadena
    Acceleron Pharma Inc, 128 Sidney St, Cambridge, MA 02139, USA
    J Appl Physiol (1985) 109:635-42. 2010
  7. doi request reprint ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth
    Dianne Mitchell
    Acceleron Pharma, Cambridge, MA 02139, USA
    Mol Cancer Ther 9:379-88. 2010
  8. ncbi request reprint Identification of MAGI-3 as a transforming growth factor-alpha tail binding protein
    Jeffrey L Franklin
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Exp Cell Res 303:457-70. 2005

Collaborators

  • Deanna Smith
  • Mary Bouxsein
  • ERNESTO M CANALIS
  • Ravindra Kumar
  • Asya V Grinberg
  • Kathryn W Underwood
  • Rajasekhar N V S Suragani
  • Dianne Sako
  • Jasbir Seehra
  • Roselyne Castonguay
  • Aaron W Mulivor
  • Samuel M Cadena
  • Dianne Mitchell
  • Travis E Monnell
  • Sharon M Cawley
  • Mark J Alexander
  • Robert Li
  • Monique V Davies
  • Nicolas Solban
  • Jeffrey A Ucran
  • Kathleen N Tomkinson
  • Eileen G Pobre
  • Jeffrey L Franklin
  • Stefano Rivella
  • Kenneth S Loveday
  • Samantha Wallner
  • Rajesh Chopra
  • Sara Gardenghi
  • John D Quisel
  • Matthew Devine
  • Robert G Matthews
  • Eleonora Presman
  • Eric D Werner
  • Erik Martinez-Hackert
  • Matthew S Spaits
  • Silas Maniatis
  • Amy J Andreucci
  • June Liu
  • Jennifer L Lachey
  • David Threadgill
  • Peter J Dempsey
  • Galina Bogatcheva
  • Robert J Coffey
  • Katherine S Meise
  • Loice Jeyakumar
  • Kenta Yoshiura

Detail Information

Publications8

  1. pmc A soluble activin type IIA receptor induces bone formation and improves skeletal integrity
    R Scott Pearsall
    Acceleron Pharma, Inc, 149 Sidney Street, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 105:7082-7. 2008
    ..These observations support the development of this pharmacological strategy for the treatment of diseases with skeletal fragility...
  2. pmc Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth
    Roselyne Castonguay
    Acceleron Pharma, Cambridge, Massachusetts 02139, USA
    J Biol Chem 286:30034-46. 2011
    ..Together our findings indicate an important role of soluble endoglin ECD in the regulation of angiogenesis and highlight efficacy of endoglin-Fc as a potential anti-angiogenesis therapeutic agent...
  3. ncbi request reprint Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis
    Rajasekhar N V S Suragani
    Acceleron Pharma, Cambridge, Massachusetts, USA
    Nat Med 20:408-14. 2014
    ..These findings implicate transforming growth factor-β (TGF-β) superfamily signaling in erythroid maturation and identify ACE-536 as a new potential treatment for anemia, including that caused by ineffective erythropoiesis. ..
  4. pmc Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia
    Rajasekhar N V S Suragani
    Acceleron Pharma, Cambridge, MA and
    Blood 123:3864-72. 2014
    ....
  5. pmc Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb
    Dianne Sako
    Acceleron Pharma, Cambridge, MA 02139, USA
    J Biol Chem 285:21037-48. 2010
    ..Together, our findings reveal binding specificity and activity determinants of the ActRIIB receptor that combine to effect specificity in the activation of distinct signaling pathways...
  6. pmc Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type
    Samuel M Cadena
    Acceleron Pharma Inc, 128 Sidney St, Cambridge, MA 02139, USA
    J Appl Physiol (1985) 109:635-42. 2010
    ..Future studies should be undertaken to confirm that the observed effects are not age dependent or due to the relatively short study duration...
  7. doi request reprint ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth
    Dianne Mitchell
    Acceleron Pharma, Cambridge, MA 02139, USA
    Mol Cancer Ther 9:379-88. 2010
    ..These data show the efficacy of chimeric ALK1-Fc proteins in mitigating vessel formation and support the view that ALK1-Fc is a powerful antiangiogenic agent capable of blocking vascularization...
  8. ncbi request reprint Identification of MAGI-3 as a transforming growth factor-alpha tail binding protein
    Jeffrey L Franklin
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Exp Cell Res 303:457-70. 2005
    ....